Payments Royalties and Reports Sample Clauses

Payments Royalties and Reports. 3.0 Coordination of Payments under the US Agreement. The license fee, milestone payments and royalties payable by SPL under this Article III are in consideration for the rights and licenses granted to SPL under this Agreement and are in addition to any amounts payable to Licensor under the US Agreement. It is understood and agreed that, with respect to the development milestone payable under Section 3.2(a)(i) and the sales milestones payable under Section 3.2(b) the occurrence of one or more of such milestone events will result in milestone payment obligations under both this Agreement and the corresponding provisions of the US Agreement. It is further understood that SPL's financial obligations with respect to development costs under Article II shall be [ * ] apportioned between SPL and the corresponding obligations of Schering Corporation under the US Agreement.
AutoNDA by SimpleDocs
Payments Royalties and Reports. 3.0 Coordination of Payments under the International Agreement. The license fee, milestone payments and royalties payable by Schering under this Article III are in consideration for the rights and licenses granted to Schering under this Agreement and are in addition to any amounts payable to Licensor under the International Agreement. It is understood and agreed that, with respect to the development milestone payable under Section 3.2(a)(i) and the sales milestones payable under Section 3.2(b) the occurrence of one or more of such milestone events will result in milestone payment obligations under both this Agreement and the corresponding provisions of the International Agreement. It is further understood that Schering's financial obligations with respect to development costs under Article II shall be [ * ] apportioned between Schering and the corresponding obligations of Schering-Plough Ltd. under the International Agreement.
Payments Royalties and Reports. 4.01 In consideration for the licenses granted to LICENSEE hereunder, LICENSEE and permitted Affiliates of LICENSEE shall pay to LICENSOR in the manner set forth below, payable quarterly, royalties on the annual Net Sales of Licensed Products made during such quarter by LICENSEE or Affiliates according to the following schedule:
Payments Royalties and Reports. 6.1 [Intentionally omitted].
Payments Royalties and Reports. 32 6.1 Initial License Payment 32 6.2 Equity Investment 32 6.3 Programs Funding. 33 6.4 Development Milestone Payments. 34 6.5 Sales Milestone Payments. 35 6.6 Royalties 36 6.7 Reports; Payments 37 6.8 Books and Records; Audit Rights 37 6.9 Taxes 38 6.10 United States Dollars 38 6.11 Payment Method and Currency Conversion 38 6.12 Blocked Payments 39 6.13 Late Payments 39 ARTICLE VII PATENTS 39 7.1 Ownership. 39 7.2 BI Prosecution and Maintenance of Patent Rights 40 7.3 MacroGenics Prosecution and Maintenance of Patent Rights 40 7.4 Prosecution and Maintenance of Joint Patent Rights and Collaboration DART Patent Rights 40 7.5 Third Party Infringement. 42 7.6 Patent Invalidity Claim. 43 7.7 Patent Term Extensions 44 7.8 Patent Marking 44 ARTICLE VIII CONFIDENTIALITY AND PUBLICATION 44 8.1 Nondisclosure Obligation 44 8.2 Authorized Disclosure 44 8.3 Scientific Publications 45 8.4 Press Releases and Other Permitted Disclosures. 45
Payments Royalties and Reports. 5.1 RESEARCH PROGRAM FUNDING
Payments Royalties and Reports. 8 5.1. License Fee....................................................................................8 5.2.
AutoNDA by SimpleDocs
Payments Royalties and Reports. 3.1 In consideration of the sublicense granted herein, SUBLICENSEE shall pay to ALLERGAN the royalties payable by “LICENSEE” set forth in Article 4.01 of the Prior License Agreement.
Payments Royalties and Reports. 5.1 Commitment Fee and Option Payment. In consideration for Transcell's commitment to perform its obligations under the Research Program and for access to the Transcell Know-How and Patent Assets granted hereunder, Merck shall pay to Transcell a non- refundable commitment fee of $1,500,000 within thirty (30) days after the Effective Date. In consideration for the option granted in Section 3.3 hereof, Merck shall pay to Transcell a non-refundable Option Payment of $1,000,000 within thirty (30) days after the Effective Date.
Payments Royalties and Reports. 15 5.1 Commitment Fee and Option Payment................................................... 15 5.2
Time is Money Join Law Insider Premium to draft better contracts faster.